The Perella Weinberg Partners Capital Management LP Invests $2,104,000 in Cepheid (CPHD)

The Perella Weinberg Partners Capital Management LP Invests $2,104,000 in Cepheid (CPHD)

Perella Weinberg Partners Capital Management LP bought a new stake in shares of Cepheid (NASDAQ:CPHD) during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 39,927 shares of the company’s stock, valued at approximately $2,104,000.

Several other institutional investors also recently added to or reduced their stakes in the stock. First Mercantile Trust Co. boosted its stake in shares of Cepheid by 6.6% in the second quarter. First Mercantile Trust Co. now owns 4,020 shares of the company’s stock valued at $124,000 after buying an additional 250 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Cepheid by 13.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,486 shares of the company’s stock valued at $131,000 after buying an additional 299 shares in the last quarter. Globeflex Capital L P purchased a new stake in shares of Cepheid during the second quarter valued at $145,000. Advisor Group Inc. purchased a new stake in shares of Cepheid during the second quarter valued at $145,000. Finally, Pacer Advisors Inc. purchased a new stake in shares of Cepheid during the second quarter valued at $166,000. 95.75% of the stock is currently owned by hedge funds and other institutional investors.

Cepheid (NASDAQ:CPHD) remained flat at $52.95 during mid-day trading on Thursday. Cepheid has a 1-year low of $25.09 and a 1-year high of $53.91. The company’s 50 day moving average is $52.75 and its 200-day moving average is $38.36.

CPHD has been the subject of a number of analyst reports. Canaccord Genuity restated a “hold” rating on shares of Cepheid in a research note on Tuesday, November 22nd. TheStreet upgraded Cepheid from a “sell” rating to a “hold” rating in a research note on Wednesday, September 28th. Fourteen equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $41.69.

About Cepheid

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.

Want to see what other hedge funds are holding CPHD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cepheid (NASDAQ:CPHD).

Related posts

Leave a Comment